Skip to content
10-Q

Quarterly Report

Neuphoria Therapeutics Inc. NEUP

0001193125-25-281579

← back to feed
Filed
Nov 14, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Nov 13, 2025 5.38M sh
Shares Diluted Q1 2025 · Sep 30, 2025 2.25M sh
Shares Diluted restated Q1 2025 · Sep 30, 2024 1.3M sh
Operating Cash Flow Q1 2025 · Sep 30, 2025 −$3.79M
Operating Cash Flow Q1 2025 · Sep 30, 2024 −$4.43M
Cash And Equivalents Q1 2025 · Sep 30, 2025 $13.65M
Cash And Equivalents Q1 2025 · Jun 30, 2025 $14.21M
Cash And Equivalents Q1 2025 · Sep 30, 2024 $8.08M
Stockholders Equity Q1 2025 · Sep 30, 2025 $12.51M
Stockholders Equity Q1 2025 · Jun 30, 2025 $19M
Stockholders Equity Q1 2025 · Sep 30, 2024 $17.07M
Stockholders Equity Q1 2025 · Jun 30, 2024 $17.49M
Current Liabilities Q1 2025 · Sep 30, 2025 $5.12M
Current Liabilities Q1 2025 · Jun 30, 2025 $4.22M
Total Liabilities Q1 2025 · Sep 30, 2025 $14.83M
Total Liabilities Q1 2025 · Jun 30, 2025 $9.59M
Current Assets Q1 2025 · Sep 30, 2025 $13.95M
Current Assets Q1 2025 · Jun 30, 2025 $15.04M
Total Assets Q1 2025 · Sep 30, 2025 $27.34M
Total Assets Q1 2025 · Jun 30, 2025 $28.59M
Eps Diluted Q1 2025 · Sep 30, 2025 −$4.41
Eps Diluted restated Q1 2025 · Sep 30, 2024 −$0.62
Eps Basic Q1 2025 · Sep 30, 2025 −$4.41
Eps Basic restated Q1 2025 · Sep 30, 2024 −$0.62
Sga Expense Q1 2025 · Sep 30, 2025 $1.87M
Sga Expense Q1 2025 · Sep 30, 2024 $1.67M
Rd Expense Q1 2025 · Sep 30, 2025 $3.79M
Rd Expense Q1 2025 · Sep 30, 2024 $1.9M
Net Income Q1 2025 · Sep 30, 2025 −$9.91M
Net Income Q1 2025 · Jun 30, 2025 −$400K
Net Income Q1 2025 · Sep 30, 2024 −$804.79K
Operating Income Q1 2025 · Sep 30, 2025 −$5.65M
Operating Income Q1 2025 · Sep 30, 2024 −$3.57M